Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression

FDA granted accelerated approival to Emrelis (telisotuzumab vedotin-tllv) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.

May 16, 2025

Vol.51 No.19

Advancing quality of life in oncology: A journey of compassion and innovation

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion.

David Ryan named president of Mass General Brigham Cancer Institute

David Ryan was named the inaugural president of the Mass General Brigham’s Cancer Institute following a national search process.

May 02, 2025

Vol.51 No.17

Cancer Policy

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.

April 11, 2025

Vol.51 No.14

By Claire Marie Porter

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression

Advancing quality of life in oncology: A journey of compassion and innovation

David Ryan named president of Mass General Brigham Cancer Institute

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Renew today!

Subscriber content

Never miss an issue!

Login

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression

Advancing quality of life in oncology: A journey of compassion and innovation

David Ryan named president of Mass General Brigham Cancer Institute

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Only half of adolescents and young adults with cancer get fertility counseling before treatmentOncofertility consult is an oft-overlooked standard of care

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care